PURPOSE: To retrospectively determine whether nonpalpable solid breast masses that were partially or completely obscured at mammography and diagnosed as probably benign only at ultrasonography (US) can be safely managed with follow-up. MATERIALS AND METHODS: The local ethics committee approved this study; informed consent was not required. In 409 women, 448 nonpalpable solid masses were identified and classified as probably benign at US; at mammography these masses were either partially or completely obscured by dense fibroglandular tissue. Of the 448 masses, 445 were followed up, while biopsy was performed after initial imaging in the remaining three. False-negative rates, negative predictive values (NPVs), and exact 95% confidence intervals (CIs) were calculated. RESULTS: Of the 445 masses, 442 remained stable at follow-up (range, 2-5 years; mean, 3.3 years). Two masses increased (fibroadenomas at biopsy). One mass became palpable, and cancer was diagnosed at biopsy. The three masses in which initial biopsy was performed were fibroadenomas. The false-negative rate was 0.2% (one of 448; NPV, 99.8%; 95%CI: 0.0%, 1.23%). CONCLUSION: Follow-up US appears to be an acceptable alternative to biopsy for solid masses with benign morphologic features seen at US owing to the extremely high NPV (99.8%). (c) RSNA, 2007.
PURPOSE: To retrospectively determine whether nonpalpable solid breast masses that were partially or completely obscured at mammography and diagnosed as probably benign only at ultrasonography (US) can be safely managed with follow-up. MATERIALS AND METHODS: The local ethics committee approved this study; informed consent was not required. In 409 women, 448 nonpalpable solid masses were identified and classified as probably benign at US; at mammography these masses were either partially or completely obscured by dense fibroglandular tissue. Of the 448 masses, 445 were followed up, while biopsy was performed after initial imaging in the remaining three. False-negative rates, negative predictive values (NPVs), and exact 95% confidence intervals (CIs) were calculated. RESULTS: Of the 445 masses, 442 remained stable at follow-up (range, 2-5 years; mean, 3.3 years). Two masses increased (fibroadenomas at biopsy). One mass became palpable, and cancer was diagnosed at biopsy. The three masses in which initial biopsy was performed were fibroadenomas. The false-negative rate was 0.2% (one of 448; NPV, 99.8%; 95%CI: 0.0%, 1.23%). CONCLUSION: Follow-up US appears to be an acceptable alternative to biopsy for solid masses with benign morphologic features seen at US owing to the extremely high NPV (99.8%). (c) RSNA, 2007.
Authors: Amy Lynn Conners; Carrie B Hruska; Cindy L Tortorelli; Robert W Maxwell; Deborah J Rhodes; Judy C Boughey; Wendie A Berg Journal: Eur J Nucl Med Mol Imaging Date: 2012-06 Impact factor: 9.236
Authors: Linda M Sanders; Pinky Sharma; Miriam El Madany; Alexander B King; Koren S Goodman; Alison Esteva Sanders Journal: Pediatr Radiol Date: 2017-10-27
Authors: Laura Holzer-Fruehwald; Matthias Meissnitzer; Michael Weber; Stephan Holzer; Klaus Hergan; Christian Weismann Journal: Ultrasound Int Open Date: 2017-09-01
Authors: Emel Durmaz; Murat Alp Öztek; Hatice Arıöz Habibi; Uğur Kesimal; Hakkı Timur Sindel Journal: Diagn Interv Radiol Date: 2017 Nov-Dec Impact factor: 2.630